Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik De Clercq

Showing results (1-10 of 866) with videos related to

Pageof 87
Sort By:
Annual Review of Pharmacology and Toxicology|September 3, 2010
A 40-year journey in search of selective antiviral chemotherapyErik De Clercq
Pharmacology & Therapeutics|September 10, 2010
Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizersErik De Clercq
Future Medicinal Chemistry|March 24, 2011
Antiviral therapy: quo vadis?Erik De Clercq
Advances in Pharmacology (San Diego, Calif.)|July 27, 2013
The Holý Trinity: the acyclic nucleoside phosphonatesErik De Clercq
Antiviral Chemistry & Chemotherapy|February 20, 2019
Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug AdministrationErik De Clercq
Expert Review of Anti-Infective Therapy|April 7, 2006
Potential antivirals and antiviral strategies against SARS coronavirus infectionsErik De Clercq
Clinical Microbiology Reviews|October 15, 2003
Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infectionsErik De Clercq
Biochemical Pharmacology|December 29, 2012
Antivirals: past, present and futureErik De Clercq
Biochemical Pharmacology|April 17, 2012
Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination eraErik De Clercq
Medicinal Research Reviews|May 15, 2012
Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?Erik De Clercq
Pageof 87

Showing results (1-10 of 866) with videos related to

Sort By:
Pageof 87
Annual Review of Pharmacology and Toxicology|September 3, 2010
A 40-year journey in search of selective antiviral chemotherapyErik De Clercq
Pharmacology & Therapeutics|September 10, 2010
Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizersErik De Clercq
Future Medicinal Chemistry|March 24, 2011
Antiviral therapy: quo vadis?Erik De Clercq
Advances in Pharmacology (San Diego, Calif.)|July 27, 2013
The Holý Trinity: the acyclic nucleoside phosphonatesErik De Clercq
Antiviral Chemistry & Chemotherapy|February 20, 2019
Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug AdministrationErik De Clercq
Expert Review of Anti-Infective Therapy|April 7, 2006
Potential antivirals and antiviral strategies against SARS coronavirus infectionsErik De Clercq
Clinical Microbiology Reviews|October 15, 2003
Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infectionsErik De Clercq
Biochemical Pharmacology|December 29, 2012
Antivirals: past, present and futureErik De Clercq
Biochemical Pharmacology|April 17, 2012
Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination eraErik De Clercq
Medicinal Research Reviews|May 15, 2012
Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?Erik De Clercq
Pageof 87